OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment

Pooled results from the PREEMPT randomized clinical trial program

Richard B. Lipton, Noah L. Rosen, Jessica Ailani, Ronald E. Degryse, Patrick J. Gillard, Sepideh F. Varon

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). Methods Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ≥2.3 and ≥5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively. Results A total of 1236 participants (O/O, n = 607; P/O, n = 629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p <0.001). The OL phase showed significantly reduced HIT-6 for O/O versus P/O at weeks 28, 36, and 48, but not 56. All three MSQ domains showed improved HRQoL relative to baseline, but only the role restrictive domain showed a significant difference between O/O and P/O at week 56. Conclusions Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.

Original languageEnglish (US)
Pages (from-to)899-908
Number of pages10
JournalCephalalgia
Volume36
Issue number9
DOIs
StatePublished - Aug 1 2016

Fingerprint

Migraine Disorders
Randomized Controlled Trials
Quality of Life
Research
Therapeutics
Placebos
onabotulinumtoxinA

Keywords

  • Chronic migraine
  • health-related quality of life
  • HIT-6
  • MSQ
  • onabotulinumtoxinA
  • prophylaxis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment : Pooled results from the PREEMPT randomized clinical trial program. / Lipton, Richard B.; Rosen, Noah L.; Ailani, Jessica; Degryse, Ronald E.; Gillard, Patrick J.; Varon, Sepideh F.

In: Cephalalgia, Vol. 36, No. 9, 01.08.2016, p. 899-908.

Research output: Contribution to journalArticle

Lipton, Richard B. ; Rosen, Noah L. ; Ailani, Jessica ; Degryse, Ronald E. ; Gillard, Patrick J. ; Varon, Sepideh F. / OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment : Pooled results from the PREEMPT randomized clinical trial program. In: Cephalalgia. 2016 ; Vol. 36, No. 9. pp. 899-908.
@article{f02bf0cc574949c2bb40dacd3f7deee9,
title = "OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program",
abstract = "Background Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). Methods Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ≥2.3 and ≥5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively. Results A total of 1236 participants (O/O, n = 607; P/O, n = 629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p <0.001). The OL phase showed significantly reduced HIT-6 for O/O versus P/O at weeks 28, 36, and 48, but not 56. All three MSQ domains showed improved HRQoL relative to baseline, but only the role restrictive domain showed a significant difference between O/O and P/O at week 56. Conclusions Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.",
keywords = "Chronic migraine, health-related quality of life, HIT-6, MSQ, onabotulinumtoxinA, prophylaxis",
author = "Lipton, {Richard B.} and Rosen, {Noah L.} and Jessica Ailani and Degryse, {Ronald E.} and Gillard, {Patrick J.} and Varon, {Sepideh F.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1177/0333102416652092",
language = "English (US)",
volume = "36",
pages = "899--908",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment

T2 - Pooled results from the PREEMPT randomized clinical trial program

AU - Lipton, Richard B.

AU - Rosen, Noah L.

AU - Ailani, Jessica

AU - Degryse, Ronald E.

AU - Gillard, Patrick J.

AU - Varon, Sepideh F.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). Methods Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ≥2.3 and ≥5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively. Results A total of 1236 participants (O/O, n = 607; P/O, n = 629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p <0.001). The OL phase showed significantly reduced HIT-6 for O/O versus P/O at weeks 28, 36, and 48, but not 56. All three MSQ domains showed improved HRQoL relative to baseline, but only the role restrictive domain showed a significant difference between O/O and P/O at week 56. Conclusions Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.

AB - Background Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). Methods Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ≥2.3 and ≥5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively. Results A total of 1236 participants (O/O, n = 607; P/O, n = 629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p <0.001). The OL phase showed significantly reduced HIT-6 for O/O versus P/O at weeks 28, 36, and 48, but not 56. All three MSQ domains showed improved HRQoL relative to baseline, but only the role restrictive domain showed a significant difference between O/O and P/O at week 56. Conclusions Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.

KW - Chronic migraine

KW - health-related quality of life

KW - HIT-6

KW - MSQ

KW - onabotulinumtoxinA

KW - prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84979609041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979609041&partnerID=8YFLogxK

U2 - 10.1177/0333102416652092

DO - 10.1177/0333102416652092

M3 - Article

VL - 36

SP - 899

EP - 908

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 9

ER -